Barinthus Biotherapeutics (BRNS) Institutional Ownership $1.19 -0.01 (-0.42%) Closing price 04:00 PM EasternExtended Trading$1.18 0.00 (-0.42%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$878.82KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$495.14K Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data BRNS Institutional Buying and Selling by Quarter Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Gilead Sciences Inc.99,478$93K0.0%-73.1%0.247% 8/13/2025 Baird Financial Group Inc.192,461$179K0.0%+108.2%0.477% 5/13/2025 Gilead Sciences Inc.369,855$360K0.0%-40.4%0.917% 5/13/2025 HighTower Advisors LLC37,450$36K0.0%N/A0.093% 2/14/2025 Gilead Sciences Inc.620,351$749K0.0%N/A1.542% 8/2/2024 Alphabet Inc.1,513,644$2.12M0.1%N/A3.878% 7/24/2024 Catalina Capital Group LLC17,819$25K0.0%N/A0.046% 7/16/2024 Ipswich Investment Management Co. Inc.23,075$32K0.0%N/A0.059% 7/16/2024 M&G Plc5,197,349$7.28M0.0%N/A13.316% 5/16/2024 BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024 DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, 9 institutional investors and hedge funds held shares of Barinthus Biotherapeutics. The most heavily invested institutionals were M&G Plc ($7.28M), Alphabet Inc. ($2.12M), DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M), Baird Financial Group Inc. ($179K), Gilead Sciences Inc. ($93K), and HighTower Advisors LLC ($36K).Learn more on Barinthus Biotherapeutics' institutional investors. What percentage of Barinthus Biotherapeutics' stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics' stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics' stock? Of the 9 institutional investors that purchased Barinthus Biotherapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: M&G Plc ($5.20M), Alphabet Inc. ($1.51M), DC Funds LP ($642.20K), Gilead Sciences Inc. ($620.35K), BlueCrest Capital Management Ltd ($542.67K), Baird Financial Group Inc. ($100K), and HighTower Advisors LLC ($37.45K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 757,801 shares in the last 24 months. This purchase volume represents approximately $878.82K in transactions. Which of Barinthus Biotherapeutics' major shareholders have been selling company stock? The following institutional investors have sold Barinthus Biotherapeutics stock in the last 24 months: Gilead Sciences Inc. ($520.87K). How much institutional selling is happening at Barinthus Biotherapeutics? Institutional investors have sold a total of 520,873 shares in the last 24 months. This volume of shares sold represents approximately $495.14K in transactions. Related Companies EPRX Institutional Ownership MDWD Institutional Ownership ENGN Institutional Ownership KRRO Institutional Ownership SLS Institutional Ownership TVGN Institutional Ownership ENTA Institutional Ownership CRBU Institutional Ownership LFVN Institutional Ownership ACTU Institutional Ownership This page (NASDAQ:BRNS) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access